AbbVie (NYSE:ABBV) Raised to Strong-Buy at Wall Street Zen

AbbVie (NYSE:ABBV) was upgraded by Wall Street Zen from a “buy” rating to a “strong-buy” rating in a research report issued on Saturday.

Several other research firms have also commented on ABBV. Cantor Fitzgerald set a $250.00 price objective on AbbVie and gave the stock an “overweight” rating in a research report on Thursday, October 9th. Weiss Ratings reissued a “hold (c)” rating on shares of AbbVie in a research report on Wednesday, October 8th. BMO Capital Markets upped their price objective on AbbVie from $215.00 to $240.00 and gave the company an “outperform” rating in a research report on Friday, September 12th. Evercore ISI lifted their price objective on AbbVie from $207.00 to $222.00 and gave the stock an “outperform” rating in a research report on Monday, September 22nd. Finally, Citigroup cut their target price on shares of AbbVie from $240.00 to $235.00 and set a “neutral” rating for the company in a research note on Monday, November 3rd. Three research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and eight have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $244.55.

AbbVie Stock Down 0.2%

Shares of NYSE:ABBV opened at $223.45 on Friday. The company has a quick ratio of 0.60, a current ratio of 0.72 and a debt-to-equity ratio of 44.14. The company has a market cap of $394.92 billion, a price-to-earnings ratio of 169.28, a PEG ratio of 1.21 and a beta of 0.36. AbbVie has a fifty-two week low of $164.39 and a fifty-two week high of $244.81. The firm’s 50-day simple moving average is $227.25 and its 200-day simple moving average is $209.59.

AbbVie (NYSE:ABBV) last posted its quarterly earnings results on Friday, October 31st. The company reported $1.86 earnings per share for the quarter, topping analysts’ consensus estimates of $1.77 by $0.09. The business had revenue of $15.78 billion for the quarter, compared to analysts’ expectations of $15.58 billion. AbbVie had a net margin of 4.00% and a return on equity of 3,216.47%. The business’s revenue for the quarter was up 9.1% on a year-over-year basis. During the same period in the prior year, the company posted $3.00 EPS. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. As a group, equities research analysts predict that AbbVie will post 12.31 earnings per share for the current year.

Institutional Investors Weigh In On AbbVie

A number of hedge funds have recently bought and sold shares of ABBV. Chelsea Counsel Co. bought a new position in shares of AbbVie during the third quarter worth about $26,000. TD Capital Management LLC raised its stake in AbbVie by 82.9% during the first quarter. TD Capital Management LLC now owns 128 shares of the company’s stock valued at $27,000 after buying an additional 58 shares in the last quarter. Marshall & Sullivan Inc. WA acquired a new stake in AbbVie during the second quarter valued at approximately $25,000. Texas Capital Bancshares Inc TX bought a new position in AbbVie during the 3rd quarter worth approximately $31,000. Finally, Evolution Wealth Management Inc. acquired a new position in shares of AbbVie in the 2nd quarter worth approximately $26,000. Institutional investors and hedge funds own 70.23% of the company’s stock.

About AbbVie

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.